SCHEMBL2563593

SCHEMBL2563593

Fc1ccc(CBr)c2ncccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 13/20 0.56
L3MBTL1 Q9Y468 8/20 0.56
MPI P34949 2/20 0.56
HTR5A P47898 1/20 0.48
SLC40A1 Q9NP59 1/20 0.42
LMNA P02545 4/20 0.42
NPC1 O15118 3/20 0.42
HTT P42858 2/20 0.42
RAB9A P51151 2/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
KMT2A Q03164 3/20 0.40
TDP1 Q9NUW8 3/20 0.40
USP2 O75604 2/20 0.40
ALOX12 P18054 2/20 0.40
MITF O75030 1/20 0.40
HSD17B10 Q99714 1/20 0.40
RECQL P46063 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13462244 0.82 KDM4E (0.56) KDM4EL3MBTL1MPIHTR5ASLC40A1
SCHEMBL21979163 0.80 KMT2A (0.56) KDM4EL3MBTL1MPISLC40A1LMNA
SCHEMBL30901310 0.80 KMT2A (0.56) KDM4EL3MBTL1MPISLC40A1LMNA
SCHEMBL19990071 0.78 KDM4E (0.70) KDM4EL3MBTL1MPIHTR5ASLC40A1
SCHEMBL29937553 0.76 KDM4E (0.61) KDM4EL3MBTL1MPIHTR5ASLC40A1
SCHEMBL3558147 0.76 KDM4E (0.61) KDM4EL3MBTL1MPIHTR5ASLC40A1
SCHEMBL29578967 0.75 KDM4E (0.41) KDM4EL3MBTL1MPILMNANPC1
SCHEMBL3530022 0.75 LRRK2 (0.41) KDM4EL3MBTL1SLC40A1LMNANPC1
SCHEMBL30002514 0.74 KDM4E (0.46) KDM4EL3MBTL1MPISLC40A1LMNA
SCHEMBL28892163 0.74 KDM4E (0.46) KDM4EL3MBTL1MPISLC40A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200131144-A1 AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS PHENEX-FXR GMBH (DE) 2020-04-30 US disclosed
WO-2019016269-A1 AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS PHENEX-FXR GMBH (DE) 2019-01-24 WO disclosed
WO-2011132051-A2 TRICYCLE COMPOUNDS AS PHOSPHODIESTERASE-10 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2011-10-27 WO disclosed
WO-2011132051-A2 TRICYCLE COMPOUNDS AS PHOSPHODIESTERASE-10 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131144-A1 AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS NR1H2, NR1H3, NR1H4 KDM4E 2569/4885L3MBTL1 2981/4885MPI 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.